Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from NervGen Pharma ( (TSE:NGEN) ) is now available.
NervGen Pharma announced a virtual investor event to discuss its Phase 1b/2a clinical trial for NVG-291, a therapeutic peptide aimed at nervous system repair in spinal cord injury patients. The event will provide insights into the trial’s design and endpoints, highlighting the potential impact on spinal cord injury treatment and NervGen’s position in the biotech industry.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotech company focused on developing neurorestorative therapeutics. The company is dedicated to advancing treatments for nervous system repair, with a primary focus on spinal cord injuries.
YTD Price Performance: -21.98%
Average Trading Volume: 49,012
Technical Sentiment Signal: Buy
Current Market Cap: $128.6M
See more data about NGEN stock on TipRanks’ Stock Analysis page.